Global CDMO Reach SGS CDMO Solutions has an established global client base with over 150 collaborations and experience across pre-clinical to commercial manufacturing, signaling strong potential for expanded services in new markets and larger-scale partnerships with multinational pharmaceutical companies seeking end-to-end formulation development and manufacturing capabilities.

Specialty Niche Expertise The company’s focus on psychedelics, controlled drugs, paediatrics and niche dosage forms positions it as a go-to CDMO for novel or regulated therapies, presenting opportunities to win business from emerging biotech startups and niche pharma players requiring compliant, specialized manufacturing and analytical support.

Regulatory Readiness With MHRA and FDA inspected facilities and a comprehensive suite from pre-clinical screening to clinical supply, SGS CDMO Solutions is well placed to pursue long-term development programs and scale-up projects for clients transitioning from clinical to commercial phases, including complex regulatory submissions.

Expansion & Capabilities Recent facility expansions in China and Australia, plus new services like EUDR Readiness and advanced testing capabilities, indicate capacity for geographic and service expansion, offering sales opportunities to clients needing regional access, faster timelines, and enhanced compliance solutions across supply chains.

Technology & Compliance Edge Adoption of enterprise and project management tools (CRM, PRINCE2, Smartsheet) and a strong emphasis on validated GMP processes enable efficient project delivery and risk management, making SGS an attractive partner for clients prioritizing reliability, traceability, and scalable quality systems.